Multi-Compartment Profiling of Bacterial and Host Metabolites Identifies Intestinal Dysbiosis and Its Functional Consequences in the Critically Ill Child.
Adolescent
Child
Child, Preschool
Chromatography, Liquid
Cresols
/ urine
Critical Illness
Dysbiosis
/ diagnosis
Fatty Acids, Volatile
/ analysis
Feces
/ chemistry
Female
Formates
/ urine
Gastrointestinal Microbiome
/ physiology
Hippurates
/ urine
Humans
Infant
Intensive Care Units, Pediatric
/ organization & administration
Magnetic Resonance Imaging
Male
Mass Spectrometry
Metabolomics
Prospective Studies
RNA, Ribosomal, 16S
Respiration, Artificial
/ statistics & numerical data
Severity of Illness Index
Sulfuric Acid Esters
/ urine
Time Factors
United Kingdom
Urine
/ chemistry
Journal
Critical care medicine
ISSN: 1530-0293
Titre abrégé: Crit Care Med
Pays: United States
ID NLM: 0355501
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
pubmed:
7
6
2019
medline:
12
5
2020
entrez:
7
6
2019
Statut:
ppublish
Résumé
Adverse physiology and antibiotic exposure devastate the intestinal microbiome in critical illness. Time and cost implications limit the immediate clinical potential of microbial sequencing to identify or treat intestinal dysbiosis. Here, we examined whether metabolic profiling is a feasible method of monitoring intestinal dysbiosis in critically ill children. Prospective multicenter cohort study. Three U.K.-based PICUs. Mechanically ventilated critically ill (n = 60) and age-matched healthy children (n = 55). Collection of urine and fecal samples in children admitted to the PICU. A single fecal and urine sample was collected in healthy controls. Untargeted and targeted metabolic profiling using 1H-nuclear magnetic resonance spectroscopy and liquid chromatography-mass spectrometry or urine and fecal samples. This was integrated with analysis of fecal bacterial 16S ribosomal RNA profiles and clinical disease severity indicators. We observed separation of global urinary and fecal metabolic profiles in critically ill compared with healthy children. Urinary excretion of mammalian-microbial co-metabolites hippurate, 4-cresol sulphate, and formate were reduced in critical illness compared with healthy children. Reduced fecal excretion of short-chain fatty acids (including butyrate, propionate, and acetate) were observed in the patient cohort, demonstrating that these metabolites also distinguished between critical illness and health. Dysregulation of intestinal bile metabolism was evidenced by increased primary and reduced secondary fecal bile acid excretion. Fecal butyrate correlated with days free of intensive care at 30 days (r = 0.38; p = 0.03), while urinary formate correlated inversely with vasopressor requirement (r = -0.2; p = 0.037). Disruption to the functional activity of the intestinal microbiome may result in worsening organ failure in the critically ill child. Profiling of bacterial metabolites in fecal and urine samples may support identification and treatment of intestinal dysbiosis in critical illness.
Identifiants
pubmed: 31169619
doi: 10.1097/CCM.0000000000003841
pmc: PMC6699985
mid: EMS82802
doi:
Substances chimiques
Cresols
0
Fatty Acids, Volatile
0
Formates
0
Hippurates
0
RNA, Ribosomal, 16S
0
Sulfuric Acid Esters
0
formic acid
0YIW783RG1
4-cresol sulfate
56M34ZQY1S
hippuric acid
TE0865N2ET
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e727-e734Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 082372
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N029399/1
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Références
J Trauma. 2006 Jan;60(1):126-33
pubmed: 16456446
J Pediatr Gastroenterol Nutr. 2007 Feb;44(2):252-7
pubmed: 17255840
Biochem Biophys Res Commun. 2007 May 11;356(3):599-603
pubmed: 17374366
World J Gastroenterol. 2007 May 28;13(20):2826-32
pubmed: 17569118
Drug Metab Pharmacokinet. 2009;24(3):201-8
pubmed: 19571431
Pediatr Crit Care Med. 2010 Mar;11(2):234-8
pubmed: 19794327
JAMA. 2009 Dec 2;302(21):2323-9
pubmed: 19952319
Physiol Rev. 1990 Apr;70(2):567-90
pubmed: 2181501
Science. 2012 Jun 8;336(6086):1262-7
pubmed: 22674330
Antimicrob Agents Chemother. 2012 Nov;56(11):5811-20
pubmed: 22948872
Curr Opin Gastroenterol. 2014 May;30(3):332-8
pubmed: 24625896
JPEN J Parenter Enteral Nutr. 2015 Jul;39(5):569-77
pubmed: 24711120
MBio. 2014 Sep 23;5(5):e01361-14
pubmed: 25249279
J Clin Invest. 2014 Oct;124(10):4212-8
pubmed: 25271726
Crit Care Med. 2015 Jul;43(7):1467-76
pubmed: 25844698
Anal Chem. 2015 Oct 6;87(19):9662-70
pubmed: 26327313
Anal Chem. 2016 May 3;88(9):4661-8
pubmed: 27065191
Sci Transl Med. 2016 Jun 15;8(343):343ra82
pubmed: 27306664
mSphere. 2016 Aug 31;1(4):null
pubmed: 27602409
Intensive Care Med. 2017 Jan;43(1):59-68
pubmed: 27837233
BMC Microbiol. 2016 Nov 14;16(1):274
pubmed: 27842515
Microbiome. 2016 Dec 29;4(1):66
pubmed: 28034303
J Proteome Res. 2017 Oct 6;16(10):3732-3740
pubmed: 28791867
Environ Microbiol. 2018 Jun;20(6):2256-2269
pubmed: 29786169
Intensive Care Med. 2018 Aug;44(8):1203-1211
pubmed: 29936583
Nat Commun. 2018 Jul 20;9(1):2872
pubmed: 30030441
PLoS One. 2018 Aug 1;13(8):e0200322
pubmed: 30067768
Sci Rep. 2018 Aug 23;8(1):12649
pubmed: 30139941
BMC Med. 2018 Nov 8;16(1):202
pubmed: 30404627
Gut. 1981 Sep;22(9):763-79
pubmed: 7028579
Circulation. 1995 Oct 15;92(8):2226-35
pubmed: 7554206
Gut. 1998 Feb;42(2):266-71
pubmed: 9536953